Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erythropoietin + probiotic
- Development stage
- Unknown
- Lead developer
- Badr University in Cairo
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
erythropoietin + probiotic is a combination therapy being developed by Badr University for the management of resistant anemia in patients with chronic kidney disease (CKD) undergoing regular hemodialysis. The combination consists of erythropoietin (EPO), a recombinant glycoprotein that stimulates erythropoiesis by binding to the erythropoietin receptor on red blood cell precursors, and a probiotic supplement, specifically Lactobacillus acidophilus. The probiotic is used as an adjuvant to improve the hematological response to EPO, potentially by modulating the gut microbiota, reducing systemic inflammation, and decreasing the levels of uremic toxins that contribute to erythropoietin resistance. This therapeutic approach is currently being evaluated in a Phase 3 clinical trial to assess its efficacy in increasing erythropoiesis-stimulating agent (ESA) responsiveness and improving overall anemia management in the CKD population.
- Other names
- erythropoietin + Lactobacillus acidophilusEPO + probiotic
02
Targets
Erythropoietin Receptor
Beyond the preview
Go deeper on erythropoietin + probiotic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erythropoietin + probiotic.